Normustine

Normustine, also known as bis(2-chloroethyl)carbamic acid, is a nitrogen mustard and alkylating antineoplastic agent (i.e., chemotherapy agent).[1][2][3] It is a metabolite of a number of antineoplastic agents that have been developed for the treatment of tumors, including estramustine phosphate, alestramustine, cytestrol acetate, and ICI-85966 (stilbostat), but only the former of which has actually been marketed.[1][2][3]

Normustine
Clinical data
Other namesBis(2-chloroethyl)carbamic acid
Identifiers
  • Bis(2-chloroethyl)carbamic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC5H9Cl2NO2
Molar mass186.03 g·mol−1
3D model (JSmol)
  • C(CCl)N(CCCl)C(=O)O
  • InChI=1S/C5H9Cl2NO2/c6-1-3-8(4-2-7)5(9)10/h1-4H2,(H,9,10)
  • Key:TTYAKTJQJVVKED-UHFFFAOYSA-N

References
  1. Brunton L, Chabner B, Knollman B (14 January 2011). Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional. p. 1709. ISBN 978-0-07-176939-6.
  2. Fox BW, Fox M (6 December 2012). Antitumor Drug Resistance. Springer Science & Business Media. pp. 199–. ISBN 978-3-642-69490-5.
  3. Decker M (5 April 2017). Design of Hybrid Molecules for Drug Development. Elsevier Science. pp. 201–. ISBN 978-0-08-101118-8.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.